Medtronic PLC $MDT Stock Holdings Boosted by Madison Asset Management LLC

Madison Asset Management LLC grew its position in shares of Medtronic PLC (NYSE:MDT) by 15.0% during the 4th quarter, Holdings Channel reports. The firm owned 195,216 shares of the medical technology company’s stock after purchasing an additional 25,527 shares during the period. Madison Asset Management LLC’s holdings in Medtronic were worth $18,752,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Curbstone Financial Management Corp grew its holdings in Medtronic by 1.8% during the fourth quarter. Curbstone Financial Management Corp now owns 5,594 shares of the medical technology company’s stock worth $537,000 after acquiring an additional 100 shares during the period. New England Capital Financial Advisors LLC raised its position in Medtronic by 7.8% in the fourth quarter. New England Capital Financial Advisors LLC now owns 1,403 shares of the medical technology company’s stock worth $135,000 after acquiring an additional 101 shares in the last quarter. Baker Tilly Wealth Management LLC lifted its holdings in Medtronic by 3.3% in the 4th quarter. Baker Tilly Wealth Management LLC now owns 3,221 shares of the medical technology company’s stock valued at $309,000 after acquiring an additional 102 shares during the last quarter. Maseco LLP boosted its position in shares of Medtronic by 32.1% during the 4th quarter. Maseco LLP now owns 444 shares of the medical technology company’s stock valued at $43,000 after purchasing an additional 108 shares in the last quarter. Finally, Holistic Financial Partners boosted its position in shares of Medtronic by 3.0% during the 3rd quarter. Holistic Financial Partners now owns 3,697 shares of the medical technology company’s stock valued at $352,000 after purchasing an additional 109 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president owned 32,768 shares in the company, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.26% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently commented on MDT. CICC Research initiated coverage on shares of Medtronic in a report on Friday, January 30th. They issued an “outperform” rating on the stock. Evercore set a $106.00 price target on shares of Medtronic and gave the stock an “outperform” rating in a research report on Thursday, April 9th. Piper Sandler dropped their price target on Medtronic from $105.00 to $91.00 and set a “neutral” rating on the stock in a report on Wednesday, April 1st. Wall Street Zen downgraded Medtronic from a “buy” rating to a “hold” rating in a research report on Saturday, April 11th. Finally, Needham & Company LLC reissued a “buy” rating and set a $120.00 price objective on shares of Medtronic in a research note on Thursday, March 26th. Fifteen research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. According to MarketBeat.com, Medtronic has a consensus rating of “Moderate Buy” and a consensus target price of $107.80.

Medtronic Stock Performance

Shares of MDT opened at $76.85 on Wednesday. The company has a 50-day moving average of $85.98 and a two-hundred day moving average of $94.01. The stock has a market cap of $98.66 billion, a price-to-earnings ratio of 21.41, a PEG ratio of 1.77 and a beta of 0.62. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. Medtronic PLC has a one year low of $74.40 and a one year high of $106.33.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The business had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. During the same quarter in the prior year, the firm earned $1.38 EPS. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities research analysts expect that Medtronic PLC will post 5.57 earnings per share for the current year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, April 17th. Stockholders of record on Friday, March 27th were issued a $0.71 dividend. The ex-dividend date was Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.7%. Medtronic’s dividend payout ratio is presently 79.11%.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Investors appear to be reacting favorably to relief from a long-running legal overhang after a False Claims Act case was dismissed, which removes a source of headline risk for Medtronic and could improve sentiment toward the stock. Medtronic shares climb as investors digest legal overhang relief and fresh cardiac-tech updates
• Positive Sentiment: Fresh updates on Medtronic’s cardiac rhythm management and broader device pipeline are reinforcing hopes for stronger product momentum, especially around newer ablation and diabetes-related offerings. Medtronic shares climb as investors digest legal overhang relief and fresh cardiac-tech updates
• Positive Sentiment: Orchestra BioMed said enrollment in the BACKBEAT pivotal trial is on track to finish by the end of Q3 2026, with data expected in Q2 2027 and a planned FDA filing afterward. Because Medtronic is the strategic collaborator, this supports a longer-term growth and pipeline narrative. Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027
• Neutral Sentiment: Medtronic also announced a California site closure as part of restructuring and portfolio consolidation in cardiovascular businesses. That may help efficiency over time, but it is more of an operational cleanup than an immediate stock catalyst. Medtronic to close California site amid restructuring
• Negative Sentiment: Medtronic has still faced recent pressure from broader healthcare-sector rotation and earlier reports of a stock decline, suggesting investors are balancing the positive legal and pipeline news against a still-soft technical backdrop. Medtronic (MDT) Stock Drops Despite Market Gains: Important Facts to Note

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).